Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells

Experimental and Molecular Medicine

Volumn 45, Issue 10, 2013, Pages

  Song, In Sung ^a   Jeong, Yu Jeong ^a   Jeong, Seung Hun ^a   Heo, Hye Jin ^a   Kim, Hyoung Kyu ^a   Lee, Sung Ryul ^a   Ko, Tae Hee ^a   Youm, Jae Boum ^a   Kim, Nari ^a   Ko, Kyung Soo ^a   Rhee, Byoung Doo ^a   Han, Jin ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

2 methoxyestradiol; bortezomib; combination therapy; multiple myeloma; resistance; superoxide dismutase 2 ROS

Indexed keywords

2 METHOXYESTRADIOL; ACETYLCYSTEINE; BORTEZOMIB; CALCIUM; MITOGEN ACTIVATED PROTEIN KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE 7; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; 2-METHOXYESTRADIOL; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; ESTRADIOL; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PYRAZINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL DEATH; CELL FRACTIONATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPLE MYELOMA; MYELOMA CELL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; METABOLISM; MITOCHONDRION; TUMOR CELL LINE; ANALOGS AND DERIVATIVES; DRUG EFFECTS;

ACETYLCYSTEINE; APOPTOSIS; BORONIC ACIDS; CALCIUM; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; HUMANS; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PYRAZINES; REACTIVE OXYGEN SPECIES;

EID: 84892402419     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.104     Document Type: Article

References (43)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
2. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-639.
3. Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 2004; 104: 2458-2466.
4. Caldera H, Giralt S. Stem cell transplantation for multiple myeloma: current status and future directions. Curr Hematol Rep 2004; 3: 249-256.
5. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
6. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008; 9: 1157-1165.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
8. Song IS, Kim HK, Lee SR, Jeong SH, Kim N, Ko KS et al. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. Int J Cancer 2013; 133: 1357-1367.
9. Seegers JC, Aveling ML, Van Aswegen CH, Cross M, Koch F, Joubert WS. The cytotoxic effects of estradiol-17 beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem 1989; 32: 797-809.
10. Sutherland TE, Anderson RL, Hughes RA, Altmann E, Schuliga M, Ziogas J et al. 2-Methoxyestradiol-a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Discov Today 2007; 12: 577-584.
11. Attalla H, Westberg JA, Andersson LC, Adlercreutz H, Makela TP. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun 1998; 247: 616-619.
12. Hamel E, Lin CM, Flynn E, D'Amato RJ. Interactions of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochemistry 1996; 35: 1304-1310.
13. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-395.
14. Kumar AP, Garcia GE, Slaga TJ. 2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 2001; 31: 111-124.
15. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000; 89: 983-994.
16. Song IS, Kim SU, Oh NS, Kim J, Yu DY, Huang SM et al. Peroxiredoxin I contributes to TRAIL resistance through suppression of redox-sensitive caspase activation in human hepatoma cells. Carcinogenesis 2009; 30: 1106-1114.
17. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 1997; 14: 379-384.
18. Qadan LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, Howard GA et al. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 2001; 285: 1259-1266.
19. Qanungo S, Basu A, Das M, Haldar S. 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene 2002; 21: 4149-4157.
20. Song IS, Jun SY, Na HJ, Kim HT, Jung SY, Ha GH et al. Inhibition of MKK7-JNK by the TOR signaling pathway regulator-like protein contributes to resistance of HCC cells to TRAIL-induced apoptosis. Gastroenterology 2012; 143: 1341-1351.
21. Ventura JJ, Cogswell P, Flavell RA, Baldwin AS Jr., Davis RJ. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 2004; 18: 2905-2915.
22. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ et al. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995; 267: 682-685.
23. Richardson PG, Hideshima T, Mitsiades C, Anderson KC. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw 2007; 5: 149-162.
24. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777-3784.
25. Djavaheri-Mergny M, Wietzerbin J, Besancon F. 2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production. Oncogene 2003; 22: 2558-2567.
26. Benhar M, Engelberg D, ROS Levitzki A. Stress-activated kinases and stress signaling in cancer. EMBO Rep 2002; 3: 420-425.
27. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 2002; 277: 10244-10250.
28. Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, Masliah E. alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J Biol Chem 2002; 277: 11465-11472.
29. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 1996; 271: 31929-31936.
30. Guo YL, Baysal K, Kang B, Yang LJ, Williamson JR. Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem 1998; 273: 4027-4034.
31. Roulston A, Reinhard C, Amiri P, Williams LT. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 1998; 273: 10232-10239.
32. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002; 192: 1-15.
33. Sano M, Fukuda K, Sato T, Kawaguchi H, Suematsu M, Matsuda S et al. ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res 2001; 89: 661-669.
34. Song IS, Kim HK, Jeong SH, Lee SR, Kim N, Rhee BD et al. Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci 2011; 12: 7163-7185.
35. Guyton KZ, Liu Y, Gorospe M, Xu Q, Holbrook NJ. Activation of mitogenactivated protein kinase by H2O2. Role in cell survival following oxidant injury. J Biol Chem 1996; 271: 4138-4142.
36. Chen K, Vita JA, Berk BC, Keaney JF Jr. c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent epidermal growth factor receptor transactivation. J Biol Chem 2001; 276: 16045-16050.
37. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
38. Ventura JJ, Hubner A, Zhang C, Flavell RA, Shokat KM, Davis RJ. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell 2006; 21: 701-710.
39. Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, Matsuda S et al. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol 2004; 6: 146-153.
40. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y et al. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 2003; 22: 3898-3909.
41. Kang SW, Chang TS, Lee TH, Kim ES, Yu DY, Rhee SG. Cytosolic peroxiredoxin attenuates the activation of Jnk and p38 but potentiates that of Erk in Hela cells stimulated with tumor necrosis factor-alpha. J Biol Chem 2004; 279: 2535-2543.
42. Gotoh Y, Cooper JA. Reactive oxygen species-and dimerizationinduced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J Biol Chem 1998; 273: 17477-17482.
43. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17: 2596-2606.